DNA methylation-based detection and prediction of cervical intraepithelial neoplasia grade 3 and invasive cervical cancer with the WID™-qCIN test.
CIN3
Cervical screening
DNA methylation
HPV
Journal
Clinical epigenetics
ISSN: 1868-7083
Titre abrégé: Clin Epigenetics
Pays: Germany
ID NLM: 101516977
Informations de publication
Date de publication:
21 11 2022
21 11 2022
Historique:
received:
06
04
2022
accepted:
10
10
2022
entrez:
22
11
2022
pubmed:
23
11
2022
medline:
25
11
2022
Statut:
epublish
Résumé
Cervical screening using primary human papilloma virus (HPV) testing and cytology is being implemented in several countries. Cytology as triage for colposcopy referral suffers from several shortcomings. HPV testing overcomes some of these but lacks specificity in women under 30. Here, we aimed to develop and validate an automatable triage test that is highly sensitive and specific independently of age and sample heterogeneity, and predicts progression to CIN3+ in HPV+ patients. The WID™-qCIN, assessing three regions in human genes DPP6, RALYL, and GSX1, was validated in both a diagnostic (case-control) and predictive setting (nested case-control), in a total of 761 samples. Using a predefined threshold, the sensitivity of the WID™-qCIN test was 100% and 78% to detect invasive cancer and CIN3, respectively. Sensitivity to detect CIN3+ was 65% and 83% for women < and ≥ 30 years of age. The specificity was 90%. Importantly, the WID™-qCIN test identified 52% of ≥ 30-year-old women with a cytology negative (cyt-) index sample who were diagnosed with CIN3 1-4 years after sample donation. We identified suitable DNAme regions in an epigenome-wide discovery using HPV+ controls and CIN3+ cases and established the WID™-qCIN, a PCR-based DNAme test. The WID™-qCIN test has a high sensitivity and specificity that may outperform conventional cervical triage tests and can in an objective, cheap, and scalable fashion identify most women with and at risk of (pre-)invasive cervical cancer. However, evaluation was limited to case-control settings and future studies will assess performance and generalisability in a randomised controlled trial.
Sections du résumé
BACKGROUND
Cervical screening using primary human papilloma virus (HPV) testing and cytology is being implemented in several countries. Cytology as triage for colposcopy referral suffers from several shortcomings. HPV testing overcomes some of these but lacks specificity in women under 30. Here, we aimed to develop and validate an automatable triage test that is highly sensitive and specific independently of age and sample heterogeneity, and predicts progression to CIN3+ in HPV+ patients.
RESULTS
The WID™-qCIN, assessing three regions in human genes DPP6, RALYL, and GSX1, was validated in both a diagnostic (case-control) and predictive setting (nested case-control), in a total of 761 samples. Using a predefined threshold, the sensitivity of the WID™-qCIN test was 100% and 78% to detect invasive cancer and CIN3, respectively. Sensitivity to detect CIN3+ was 65% and 83% for women < and ≥ 30 years of age. The specificity was 90%. Importantly, the WID™-qCIN test identified 52% of ≥ 30-year-old women with a cytology negative (cyt-) index sample who were diagnosed with CIN3 1-4 years after sample donation.
CONCLUSION
We identified suitable DNAme regions in an epigenome-wide discovery using HPV+ controls and CIN3+ cases and established the WID™-qCIN, a PCR-based DNAme test. The WID™-qCIN test has a high sensitivity and specificity that may outperform conventional cervical triage tests and can in an objective, cheap, and scalable fashion identify most women with and at risk of (pre-)invasive cervical cancer. However, evaluation was limited to case-control settings and future studies will assess performance and generalisability in a randomised controlled trial.
Identifiants
pubmed: 36414968
doi: 10.1186/s13148-022-01353-0
pii: 10.1186/s13148-022-01353-0
pmc: PMC9682674
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
150Informations de copyright
© 2022. The Author(s).
Références
N Engl J Med. 2021 Nov 11;385(20):1908-1918
pubmed: 34758259
J Clin Oncol. 2022 Nov 20;40(33):3828-3838
pubmed: 36001862
Sex Transm Infect. 2017 Feb;93(1):56-61
pubmed: 28100761
J Med Screen. 2015 Mar;22(1):28-37
pubmed: 25403717
J Clin Virol. 2016 Feb;75:33-6
pubmed: 26748032
Lancet Oncol. 2021 Jan;22(1):20-21
pubmed: 33248466
Genes Chromosomes Cancer. 2020 Mar;59(3):168-177
pubmed: 31631454
Biopreserv Biobank. 2013 Feb;11(1):19-24
pubmed: 24845251
Int J Gynecol Cancer. 2016 Jun 2;:
pubmed: 27258725
Int J Cancer. 2016 Feb 15;138(4):992-1002
pubmed: 26317579
Clin Cancer Res. 2004 May 15;10(10):3396-400
pubmed: 15161694
Epigenomics. 2018 Jul;10(7):925-940
pubmed: 29693419
Genome Med. 2012 Mar 27;4(3):24
pubmed: 22453031
Nat Commun. 2022 Feb 1;13(1):449
pubmed: 35105882
Int J Cancer. 2014 May 1;134(9):2223-30
pubmed: 24127304
J Natl Cancer Inst. 2015 Jan 07;107(2):
pubmed: 25568167
Nat Commun. 2022 Feb 1;13(1):448
pubmed: 35105887
Cancer Cytopathol. 2015 Dec;123(12):745-54
pubmed: 26230283
Lancet. 2019 Jan 12;393(10167):169-182
pubmed: 30638582
J Natl Cancer Inst. 2015 Sep 15;107(12):djv257
pubmed: 26376685
Cancer Epidemiol Biomarkers Prev. 2004 May;13(5):882-8
pubmed: 15159323
Br J Cancer. 2019 Nov;121(11):954-965
pubmed: 31616037
Am J Clin Pathol. 2016 Sep;146(3):391-8
pubmed: 27543984
Int J Cancer. 2015 Feb 1;136(3):646-55
pubmed: 24923998
BJOG. 2021 Feb;128(3):504-514
pubmed: 32619334
Int J Cancer. 2021 Jan 15;148(2):396-405
pubmed: 32997803
J Infect Dis. 2010 Dec 15;202(12):1789-99
pubmed: 21067372
Int J Cancer. 2013 Dec 1;133(11):2681-7
pubmed: 23712523
Eur J Epidemiol. 2016 Feb;31(2):125-36
pubmed: 26769609
Lancet Oncol. 2014 Mar;15(3):315-22
pubmed: 24529697
JAMA. 2018 Aug 21;320(7):674-686
pubmed: 30140884
Lancet Oncol. 2019 Feb;20(2):229-238
pubmed: 30658933
Genome Med. 2022 Oct 19;14(1):116
pubmed: 36258199